Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00040014 |
The purpose of this study is to find out if the two different formulations of exemestane (Aromasin), oral and injectable, are equivalent in terms of pharmacodynamics and pharmacokinetics, i.e., if ultimately both formulations have the same efficacy in postmenopausal women with metastatic breast cancer who have failed previous antiestrogens therapy and are equally safe.
Condition | Intervention | Phase |
---|---|---|
Breast Neoplasms |
Drug: exemestane |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women With Advanced Breast Cancer Having Progressed on Tamoxifen. |
Estimated Enrollment: | 100 |
Study Start Date: | June 2002 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 971-ONC-0401-003 |
Study First Received: | June 18, 2002 |
Last Updated: | November 10, 2006 |
ClinicalTrials.gov Identifier: | NCT00040014 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Skin Diseases Breast Neoplasms Exemestane |
Aromatase Inhibitors Tamoxifen Breast Diseases |
Neoplasms Neoplasms by Site Molecular Mechanisms of Pharmacological Action Skin Diseases Antineoplastic Agents Therapeutic Uses |
Breast Neoplasms Enzyme Inhibitors Exemestane Aromatase Inhibitors Pharmacologic Actions Breast Diseases |